Journal Articles

Donald and Barbara Zucker School of Medicine
Academic Works

2018

New-Onset Isolated Asymptomatic Papilledema in
Two Patients Treated With Recombinant Growth
Hormone
L. A. Kanner
J. Klein
M. Gaffar
H. Pomeranz
Zucker School of Medicine at Hofstra/Northwell

G. Frank
Zucker School of Medicine at Hofstra/Northwell

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Pediatrics Commons
Recommended Citation
Kanner LA, Klein J, Gaffar M, Pomeranz H, Frank G. New-Onset Isolated Asymptomatic Papilledema in Two Patients Treated With
Recombinant Growth Hormone. . 2018 Jan 01; 57(4):Article 4682 [ p.]. Available from:
https://academicworks.medicine.hofstra.edu/articles/4682. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more
information, please contact academicworks@hofstra.edu.

HHS Public Access
Author manuscript
Author Manuscript

Clin Pediatr (Phila). Author manuscript; available in PMC 2019 April 01.
Published in final edited form as:
Clin Pediatr (Phila). 2018 April ; 57(4): 471–474. doi:10.1177/0009922817698808.

New-Onset Isolated Asymptomatic Papilledema in Two Patients
Treated With Recombinant Growth Hormone
Lauren Amanda Kanner, MD1,2, Jason Klein, MD1,3, Majida Gaffar, MD4, Howard Pomeranz,
MD4, and Graeme Frank, MD1
1Cohen

Children’s Medical Center of New York, North Shore LIJ Health System, Lake Success,
NY, USA

Author Manuscript

2University
3New

of Wisconsin–Madison, Madison, WI, USA

York University Langone Medical Center, New York, NY, USA

4Northwell

Health, Great Neck, NY, USA

Background

Author Manuscript

Growth hormone therapy is a well-recognized risk factor for the development of idiopathic
intracranial hypertension (IIH). IIH, also known as pseudotumor cerebri (PTC), is a rare
complication of growth hormone (GH) treatment. In the Kabi International Growth
Hormone Study (KIGS) of 2007, the incidence of IIH as an adverse event during
recombinant human growth hormone (rhGH) replacement for idiopathic growth hormone
deficiency (GHD) was 13/100, 000 treatment years.1 IIH developed anywhere between 2
weeks to 8 years after initiating GH therapy at a dose of 0.18 to 0.33 mg/kg/wk.1,2 IIH is
characterized by elevated intracranial pressure, papilledema, and symptoms including
headache, vision changes, nausea, and vomiting.
Herein we present 2 cases of new onset, asymptomatic papilledema in patients receiving GH
therapy for GHD.
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Case 1
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The patient was an 11-year-old non-obese female with past medical history of attention
deficit hyperactivity disorder who was being treated with Concerta 36 mg daily as well as
intermittent Ritalin 10 mg daily. She was evaluated by her pediatrician for growth failure and
resultant short stature. She was found to have GHD (peak GH on GH stimulation testing
5.32 ng/mL). Noncontrast magnetic resonance imaging (MRI) of the hypothalamic/pituitary
region was normal. She was started on growth hormone 0.26 mg/kg/wk. Seven months into
GH therapy, at a routine ophthalmology evaluation, she was found to have new-onset
papilledema (Figure 1). This papilledema was not present on a previously documented
ophthalmological examination 2 years prior. She had no symptoms of blurry vision,
diplopia, headache, dizziness, nausea, or vomiting. She was referred to the emergency room
for evaluation. Neurological exam showed no focal deficits and ophthalmologic exam again
demonstrated bilateral papilledema. A lumbar puncture was performed and the opening
pressure was 20.25 cm H2O and closing pressure of 17 cm H2O. Computed tomography of
the head, MRI of the orbit, and MRI/MR angiography of the brain were normal. MR
venography of the brain showed focal narrowing within the distal transverse sinus
bilaterally, but no evidence of venous sinus thrombosis. Laboratory work, including
comprehensive metabolic panel, thyroid function tests, complete blood count and cerebral
spinal fluid studies, lyme titers, and mycoplasma titers, were normal. She was evaluated by a
neuro-ophthalmologist who found superior temporal and inferior nasal arcuate visual field
defects in the left eye and slight enlargement of the blind spot in the right eye (Figure 2).
The patient’s GH therapy was discontinued and she was started on acetazolamide 90 mg
thrice a day. At her 4-month follow-up appointment, improvement of visual field loss was
noted. The patient followed up with neuro-ophthalmology 9 months after GH therapy was
discontinued at which point her visual field abnormalities had corrected. GH therapy was
resumed and ophthalmology follow-up was planned.
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Case 2
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The patient was a 5-year-old non-obese male with a past medical history significant for
unilateral left amblyopia, which had been routinely followed by an ophthalmologist. He was
evaluated by pediatric endocrinology due to growth failure and short stature with
longitudinal growth at the <3rd percentile and was found to have GHD (peak GH on GH
stimulation testing 6.69 ng/mL). Noncontrast MRI of the hypothalamic/pituitary region was
normal. He was started on GH at 0.284 mg/kg/wk. Seven months into GH therapy, at a
routine ophthalmology follow-up for his amblyopia, he was found to have new-onset
papilledema. He had no symptoms of blurry vision, diplopia, dizziness, headache, nausea, or
vomiting. GH therapy was discontinued. He discontinued rhGH and underwent continued
ophthalmologic follow-up. At 1 month following his diagnosis, his examination, although
improved, had not completely normalized. Evaluation by neuro-ophthalmology was planned.

Discussion
IIH is a well-recognized side effect of recombinant GH. In 1985, rhGH was introduced as a
viable and safe alternative to human pituitary GH. Initial cases of IIH associated with rhGH
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treatment were reported in 1986 and were thought to be due to the progressive trend in
higher and more frequent doses of GH during treatment. A 1993 letter to the New England
Journal of Medicine by the Food and Drug Administration3,4 discussed the link between
rhGH and IIH with respect to 23 patients (22 children, 1 adult) who presented with
headaches and papilledema during treatment with rhGH at doses between 0.21 and 0.56
mg/kg/wk. Of these 22 children, therapy was initiated for GH deficiency or short stature
from chronic renal failure, Prader-Willi syndrome, Turner syndrome, or delayed puberty.
Discontinuation of rhGH resulted in the resolution of papilledema in all but one patient. The
risk of visual deterioration, especially with continued rhGH treatment, is significant and
some patients experience a chronic disabling course for many years.5–7
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One of the cardinal physical findings of IIH is papilledema, noted on examination by
swelling of the optic disc, venous engorgement and loss of venous pulsation, as well as
blurring of the optic margins. Papilledema in cases of IIH is typically bilateral in nature,
though some cases may have asymmetric or unilateral findings. Papilledema is generally not
associated with marked loss of visual acuity or visual fields unless it has been present for a
considerable time.8,9 Chronic optic nerve edema can cause optic nerve pallor, color vision
deficiency, persistent visual field changes, and significant vision loss.
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We report 2 patients presenting with asymptomatic bilateral papilledema discovered during
routine ophthalmologic follow-up in children being treated with rhGH for idiopathic GH
deficiency. While the first patient did not have an increased opening pressure, she had
objective findings of papilledema and visual field abnormalities that resolved with
discontinuation of the GH therapy. The second patient is undergoing continued evaluation
currently for IIH. Treatment with rhGH had been started in both cases 7 months prior to
discovery of papilledema. The doses of rhGH were between 0.26 and 0.284 mg/kg/wk.
Neither patient had risk factors associated with IIH or papilledema.
These cases raise questions of both the incidence and the natural history of rhGH-related
IIH. In children with rhGH-related IIH, the spectrum of presenting signs and symptoms may
be variable, nonspecific, and broader than once thought. These cases demonstrate that
ophthalmologic findings of papilledema may precede signs and symptoms of increased
intracranial pressure. Visual loss is an important endpoint in the natural history of untreated
IIH and papilledema; temporary discontinuation of rhGH treatment with close monitoring of
resumption of normal vision is crucial in ongoing follow up for those diagnosed with the
condition. Routine ophthalmic screening beginning early in rhGH treatment has been
recommended for years,10 though it is not yet the accepted standard. Early screening may
reduce morbidity associated with growth hormone induced IIH due to early recognition.2
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It is important to recognize that optic nerve hypoplasia and other congenital disc anomalies
may be associated with GHD and can cause pseudopapilledema.11 Thus, optic disc
abnormality during GH therapy may reflect pseudopapilledema, a benign condition, and not
IIH. Nonetheless, routine screening would likely find these abnormalities prior to rhGH
therapy onset, thus excluding them from consideration of true rhGH-related papilledema and
IIH. Both our cases had complete ophthalmologic evaluation demonstrating normal optic
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nerves prior to starting GH therapy. The first was seen 2 years prior for a failed vision
screening; the second was followed for amblyopia.
Asymptomatic IHH has been described by Francois et al12 who described an 11-year-old
male with GH deficiency and empty sella syndrome with presentation of IIH after 6 months
of treatment initiation of GH therapy, with later resumption of GH therapy after resolution
with no further papilledema. In addition, Besch et al13 described 2 prepubertal females on
rhGH for growth failure who developed IIH presenting only as visual changes without
headaches, nausea, or vomiting at 3 and 18 months. Neither patient was obese nor had renal
insufficiency, both known risk factors for IIH. The diagnosis of IIH was made based on
ophthalmologic examination, elevated cerebrospinal fluid opening pressure, and normal
central nervous system imaging.
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Two factors are noteworthy about patients. In both instances, the papilledema was
asymptomatic and found incidentally. Second, the time to resolution was long. While most
patients reported in the literature have resolution of papilledema and symptoms within days
to weeks of discontinuation of growth hormone therapy, our first patient required
acetazolamide for resolution of papilledema and recovery of loss of visual field took several
months. This suggests that the pathogenesis of asymptomatic papilledema during GH
therapy may be different from the well-described IHH associated with GH therapy.
While IIH is a rare complication of rhGH treatment, it appears that papilledema may present
prior to the traditional signs and symptoms of increased intracranial pressure (headaches,
nausea/vomiting, visual changes). Routine ophthalmological screening of children with
idiopathic GHD should therefore be considered both before and during treatment with rhGH.
14
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Bilateral papilledema as noted on dilated retinal exam. (A) Right eye retinal examination
showing significant papilledema. (B) Left eye retinal examination with notable diffuse
papilledema.
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Figure 2.

Visual field losses documented for case 1 via Humphrey 24-2 visual field: Slight
enlargement of the blind spot and a slight nasal arcuate visual field defect in the right eye.
Denser superotemporal and infernasal arcuate defects in the left eye.
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